Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
NCT00624338
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
461
Enrollment
INDUSTRY
Sponsor class
Conditions
Lupus Erythematosus, Systemic
Interventions
DRUG:
Atacicept 75 mg
DRUG:
Atacicept 150 mg
OTHER:
Placebo Comparator
Sponsor
EMD Serono
Collaborators
[object Object]